GPR120 RECEPTOR AGONISTS AND USES THEREOF

1 . A compound of Formula (A)

or a pharmaceutically acceptable salt thereof, wherein:

the group J is absent or selected from the group consisting

the ring Q is selected from the group consisting of aryl, heteroaryl,

wherein Q is optionally substituted with (R 6 ) k ;

A 1 , A 2 , A 3 and A 4 are independently selected from the group consisting of N and C, with the proviso that only 0, 1 or 2 of A 1 , A 2 , A 3 and A 4 is N;

T 1 , T 2 , T 3 and T are independently selected from the group consisting of N, O, CR 1 and CR 1 R 2 , with the proviso that only 0, 1 or 2 of T 1 , T 2 , T 3 and T 4 is selected from N and O;

W 1 , W 2 , W 3 and W 4 are independently selected from the group consisting of N, NRa, CR 1 , CR 1 R 2 , O, S, S(O) and S(O) 2 , with the proviso that ring J is not 1,3-dioxolane;

E 1 , E 2 and E 3 are independently selected from the group consisting of C and N;

one of X and Y is a bond, —CH 2 —, —CHD-, or —CD 2 -, and the other of X and Y is selected from the group consisting of —CH 2 —, —CHD-, —CD 2 -, —C(O), —C(O)NR a —, —NR a —, —O—, —S—, —S(O)— and —S(O) 2 —;

L is —(CR 4 R 5 ) q wherein optionally one —(CR 4 R 5 )— is replaced with —N—, —O—, —S—, —CR 4 ═CR 5 —, or -phenyl-;

G is selected from the group consisting of —C(O)OZ and —C(O)NZ 2 ;

each Z is independently selected from the group consisting of H, alkyl and substituted alkyl;

each R 1 and R 2 is independently selected from the group consisting of H, deuterium, halo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, oxo, alkoxy, substituted alkoxy, CN, —NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —NR a C(O)R b , —SR a , —S(O)R a and —S(O) 2 R a , and optionally R 1 and R 2 can cyclize to form a C 3-7 heterocyclyl, substituted C 3-7 heterocyclyl, spiro C 3-7 heterocyclyl, substituted spiro C 3-7 heterocyclyl, C 3-7 cycloalkyl, substituted C 3-7 cycloalkyl, spiroC 3-7 cycloalkyl or spiro substituted C 3-7 cycloalkyl;

each R 3 is independently selected from the group consisting of H, halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, —C(O)NR a R b , —NR a C(O)R b , —NR a R b , aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy and —CN;

each R 4 and R 5 is independently selected from the group consisting H, deuterium, fluoro, alkyl, substituted alkyl, alkoxy and substituted alkoxy, and optionally R 4 and R 5 can cyclize to form a C 3-7 heterocyclyl, substituted C 3-7 heterocyclyl, spiro C 3-7 heterocyclyl, substituted spiro C 3-7 heterocyclyl, C 3-7 cycloalkyl, substituted C 3-7 cycloalkyl, spiroC 3-7 cycloalkyl or spiro substituted C 3-7 cycloalkyl;

each R 6 is independently selected from the group consisting of H, halo, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CN, —OR a , —NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —NR a C(O)R b , —SR a , —S(O)R a and —S(O) 2 R a ;

each of R a and R b is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, heterocyclyl, substituted heterocyclyl, alkenyl, alkynyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl;

the subscript k is 0, 1, 2 or 3;

the subscript m is 0, 1, 2 or 3; and

the subscript q is 0, 1, 2, 3 or 4.

2 . A compound of claim 1 of Formula (B):

or a pharmaceutically acceptable salt thereof, provided that W 1 and W 3 are not both O.

3 . The compound of claim 2 wherein W 1 and W 3 are independently selected from the group consisting of CR 1 R 2 and O.

4 . The compound of claim 3 of Formula (C):

or a pharmaceutically acceptable salt thereof.

5 . The compound of claim 4 , wherein E 1 , E 2 and E 3 are all C.

6 . The compound of claim 5 , wherein X is selected from the group consisting of —CH 2 —, —CHD- and —CD 2 -, and Y is O.

7 . The compound of claim 6 , wherein in L the subscript q is 2 or 3.

8 . The compound of claim 7 , wherein the subscript q is 2.

9 . The compound of claim 8 , wherein G is —C(O)OZ.

10 . The compound of claim 9 , wherein Z is H.

11 . The compound of claim 10 , wherein the subscript m is 1 or 2, and each R 3 is independently selected from the group consisting of halo, alkyl, substituted alkyl, alkoxy and substituted alkoxy.

12 . The compound of claim 11 , wherein, each R 3 is independently selected from the group consisting of F, Cl, —CH 3 , —CF 3 and —OCH 3 .

13 . The compound of claim 12 , wherein R 1 and R 2 are independently selected from the group consisting of C 1-3 alkyl and —CF 3 .

14 . (canceled)

15 . The compound of claim 1 , wherein the subscript k is 0, 1 or 2.

16 . The compound of claim 15 , wherein each R 6 is independently selected from the group consisting of fluoro, chloro, —CH 3 , —C 2 H 5 and —CF 3 .

17 . The compound of claim 1 , wherein, the ring Q is

18 . A compound of claim 17 , wherein ring J is absent and each R 3 is independently selected from the group consisting of alkoxy, substituted alkoxy and halo.

19 . (canceled)

20 . A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

21 . A method of treating a disease or condition selected from the group consisting of Type I diabetes, Type II diabetes and metabolic syndrome, said method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 .

22 . The method of claim 21 , wherein said disease is Type II diabetes.

23 . A method of lowering blood glucose in a mammal, said method comprising administering a therapeutically effective amount of a compound of claim 1 to a mammal in need of such treatment.

24 . The method of claim 23 , wherein said mammal is a human.

25 . A method of modulating GPR120 activity in a cell, said method comprising contacting said cell with a therapeutically effective amount of a compound of claim 1 .